
- /
- Supported exchanges
- / US
- / AARD.NASDAQ
Aardvark Therapeutics, Inc. Common Stock (AARD NASDAQ) stock market data APIs
Aardvark Therapeutics, Inc. Common Stock Financial Data Overview
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aardvark Therapeutics, Inc. Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Aardvark Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Aardvark Therapeutics, Inc. Common Stock Fundamental Data
Aardvark Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.68
Get Aardvark Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aardvark Therapeutics, Inc. Common Stock News

Schizophrenia drug developer LB Pharma jumps in trading debut
Worawith Ounpeng/iStock via Getty Images LB Pharmaceuticals (LBRX [https://seekingalpha.com/symbol/LBRX]) climbed ~26% on Thursday as the New York-based biopharma, focused on developing drugs for neu...


2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside
Small-cap biotech stocks, while lacking the scale and financial stability of larger pharmaceutical giants, often have high growth potential. These companies are motivated by ground-breaking research,...

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic...

Aardvark Therapeutics GAAP EPS of -$0.66
* Aardvark Therapeutics press release [https://seekingalpha.com/pr/20200202-aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and] (NASDAQ:AARD [https://seeki...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.